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Conclusion: Implementations of ART were dominated by 
offline re-planning and online BT re-planning, although 
recently online plan selection workflows have increased with 
the availability of cone-beam-CT. Advantageous dosimetric 
and outcome related patterns using ART was documented by 
the studies included the review. Despite this, clinical 
implementations have been scarce, especially regarding 
prostate and the vast amount of in silico studies available. 
Identified challenges, hindering successful clinical 
implementations, were re-contouring of target/OARs in 
addition to patient selection, aiding the focus of the 
adaptations to the more challenging patients.  
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Currently, with our highly conformal modulated radiotherapy 
techniques, we are capable of delivering high radiation doses 
to tumour volumes, whilst minimizing dose to the surrounding 
structures. However, today’s radiotherapy is based on the 
dogmatic concept of unchanging anatomy of tumors, 
surrounding normal organs and tissues, where radiotherapy 
plans solely based on pre-treatment imaging are delivered 
invariably for several weeks of treatment. Conversely, during 
a course of curative radiotherapy, tumors and to some 
extend OARs change. In the field of head and neck cancer, 
tumor and lymph nodes shrink up to 3% per day, changing 
size, shape and position. External contour modifications 
result from loss of weight and muscle mass, altering the 
geometry of the disease in relation to OARs. This leads to 
changes in the anatomy of patients, impacting the dose 
distribution that may differ significantly from what was 
planned. In this context, considerable efforts have been put 
on adaptive radiotherapy (ART), i.e. to adapt the treatment 
delivery on the basis of changes in the tumor and/or normal 
tissues during the course of radiotherapy. The aim is then to 
compensate for under-dosage of the target volumes or over-
dosage of OARs.  
Re-imaging and re-planning evidently result in an extra 
workload and cost. Therefore, although ART is an appealing 
concept, it is at present not used on a routine basis for all 
patients. The optimal implementation strategy regarding 
selection of patients and timing of imaging/replanning 
remains to be defined. Several groups are currently 
investigating these questions, and an overview of the results, 
from a physician’s perspective will be presented. 
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Adaptive radiotherapy is an emerging area of radiotherapy. In 
general there are two categories of adaptive radiotherapy 
leading to either pro-active or reactive adaptations. As the 
terms suggest, pro-active adaptation is chosen in advance of 
the patient commencing treatment, whereas reactive 
adaptation is unscheduled and arises from an unexpected 
patient change seen during treatment.  
There are 3 distinct categories for which adaptive 
radiotherapy approaches should be considered. The 
categories and most appropriate form of adaptation are given 


























































Studies of safety in radiotherapy have shown that there is a 
higher risk of deviation during handoffs between staff groups 
with tight coupling and when decisions are made under 
significant time pressure. Deviation rates of <0.5% per 
fraction have been reported1-4, leading to deviation rates in 
the range 1-2% per patient. Adaptive radiotherapy can be 
seen as increasing the complexity of handoffs and creating 
more frequent decision making points in the process under 
time pressure. In this context the introduction of adaptive 
radiotherapy needs to be made whilst mitigating the risk of 
significantly increasing deviation rates. .  
Justification is required for adaptation from the assessment 
of risks and benefits from adaptive approaches. As there is 
currently no clear clinical benefit from adaptive 
radiotherapy, new risks need to be mitigated to ensure there 
is an overall patient benefit. Once procedures have been 
developed for an adaptive approach, changes in personnel, 
training and workload are likely to be needed to ensure the 
safe use of adaptive radiotherapy. For example, there are 
significant training requirements for radiotherapy treatment 
staff when applying pro-active adaptive radiotherapy 
techniques where the most appropriate plan must be chosen 
at each treatment fraction.  
Reactive adaptation has organically arisen from the routine 
use of online image-guidance. For example using cone-beam 
CT has provided a wealth of information regarding patient 
anatomy changes during the course of radiotherapy. 
Inevitably changes in patient anatomy seen during treatment 
lead to questions regarding the appropriateness of the 
original treatment plan. It is likely that around 20% of 
patients receiving radiotherapy will have anatomy changes 
requiring assessment for appropriateness of their original 
treatment plan during the course of their treatment. 
However, modifications to treatments should only be enacted 
if the patient benefit from the change outweighs the risk of a 
deviation that could lead to worse patient outcome. Applying 
this approach is likely to lead to <5% of patients requiring a 
modification to their treatment. Therefore, at the very least, 
departments will require efficient processes for the review of 
treatment plans against changes to patient anatomy.  
In conclusion, currently the clinical justification for adaptive 
radiotherapy approaches is unclear but the adoption rate is 
likely to continue to rise due to the available technology. In 
this context there is a requirement to ensure staffing, 
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training and workload is carefully considered to mitigate risks 
to patients.  
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Purpose or Objective: During the course of head and neck 
radiotherapy, anatomical changes may lead to underdosage 
or hotspots in target volumes, and overdosage in organs at 
risk (OARs). The largest dose differences between planned 
and actual given OAR dose have been reported for the 
parotid glands (PGs). Dose increase to the PGs could lead to 
an increase of radiation induced side effects, justifying 
adaptive radiotherapy (ART) to reduce the PG dose. Still, ART 
procedures are labour intensive and only a fraction of 
patients will benefit. The aim of this study was to develop 
and validate a method to predict dose deviations from the 
planned PG mean dose, to select patients for adaptive 
radiotherapy (ART) up-front. 
 
Material and Methods: Planning and response (6 weeks after 
RT) CT-scans from 113 head and neck cancer patients (cohort 
A) were used to estimate deviations between planned and 
actually given PG mean dose (ΔDmean). Potential pre-
treatment selection parameters presented in recent 
literature were included in the analysis. Uni- and 
multivariable linear regression analysis for the endpoint PG 
ΔDmean was performed to select pre-treatment parameters 
eligible for patient selection. ROC curve analysis was 
performed to determine cut off values for selecting patients 
with PG ΔDmean larger than 3 Gy with a sensitivity in the 
range of 70-100%. The proposed method of patient selection 
was validated in another patient cohort consisting of 43 head 
and neck cancer patients who received weekly rescan CTs 
(cohort B). 
 
Results: In univariable analysis, pre-treatment parameters 
significantly associated with PG ΔDmean were: BMI, 
chemotherapy, T-stage, N-stage, volume of the GTV, tumour 
location, overlap of the PG with the high and low dose PTV, 
V20, V30, V40 and mean dose of the PG. In multivariable 
analysis, the initial PG mean dose remained the only 
significant parameter. ROC results were summarized in Table 
1. Selection of patients for dose deviations larger than 3 Gy 
with a sensitivity of 90% could be obtained by a threshold of 
the initial PG mean dose of 22.2 Gy (Table 1). This would 
select 62% of patients for ART in cohort A and 76% in cohort B 
with a corresponding precision of 29 and 19%, saving 38 and 
24% of patients from the labour-intensive ART procedure. 
 
Conclusion: We succeeded to develop a method to select 
patients for ART up-front by using the initial mean dose to 
the parotid gland. The labour of ART could be reduced by 24-
38% with 87-90% sensitivity, contributing to a more effective 
allocation of the department resources. 
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Background: Breast cancer radiotherapy reduces the risk of 
cancer recurrence and death. However it usually involves 
some radiation exposure of the heart which may increase the 
risk of subsequent heart disease. Epidemiological data 
suggest that the major coronary event rate increases by 7.4% 
per Gy mean heart dose1. Estimates of the absolute risks of 
radiation-related heart disease are needed to help 
oncologists plan each individual woman’s treatment. The 
absolute risk for an individual woman depends on her 
estimated cardiac radiation dose and her background risk of 
ischaemic heart disease in the absence of radiotherapy. 
When the risk is known, it can then be compared with the 
absolute benefit of the radiotherapy.  
 
Methods: Worldwide data on heart doses in breast cancer 
radiotherapy published during 2003-2013 were collated 
systematically. Analyses considered the variation in the 
typical mean heart dose according to various patient and 
treatment-related factors including laterality, target(s) 
irradiated and technique2. These heart doses were used to 
predict typical absolute cardiac risks from breast cancer 
radiotherapy using the dose-response relationship of a 7.4% 
per Gy increase in the rate of major coronary events.1 These 
risks were compared with estimates of the absolute benefits 
of breast cancer radiotherapy.  
 
Results: In left breast cancer, mean heart dose averaged 
over 398 regimens in 149 studies from 28 countries was 5.4 
Gy (range <0.1-28.6 Gy). In left-sided regimens that did not 
include the internal mammary chain, the average mean heart 
dose was 5.6 Gy (range <0.1-23.0) for inverse-planned 
intensity modulated radiation therapy, 3.4 Gy (range <0.1-
12.4) for tangential irradiation, 2.2 Gy (range <0.1-3.8) for 
brachytherapy and 0.5 Gy (range 0.1-0.8) for proton beam 
therapy. On average, inclusion of the left IMC doubled the 
heart dose. In 93 regimens where the left IMC was irradiated, 
average mean heart dose was around 8 Gy for most photon or 
electron techniques, and it varied little according to which 
other targets were irradiated. In right-sided breast cancer, 
the average mean heart dose was 3.3 Gy based on 45 
